Thomas Casale1, Nestor A Molfino2, Jared Silver3, Michael Bogart2, Elizabeth Packnett4, Donna McMorrow4, Joanne Wu4, Beth Hahn5. 1. Division of Allergy and Immunology, Department of Internal Medicine, University of South Florida Morsani College of Medicine, Tampa, FL, USA. 2. US Value Evidence and Outcomes, US Medical Affairs, GSK, Research Triangle Park, NC, USA. 3. US Medical Affairs, GSK, Research Triangle Park, NC, USA. 4. Life Sciences, IBM Watson Health, Cambridge, MD, USA. 5. US Value Evidence and Outcomes, US Medical Affairs, GSK, Research Triangle Park, NC, USA. Electronic address: eth.a.hahn@gsk.com.
Abstract
BACKGROUND: Patients with severe asthma frequently have associated comorbidities, which can compound existing symptoms, complicating asthma management. OBJECTIVE: To describe mepolizumab's real-world effectiveness in patients with severe asthma stratified by common overlapping comorbidities. METHODS: This was a retrospective analysis of patients with asthma from the MarketScan Commercial and Medicare Supplemental Database initiating mepolizumab treatment (index date). Eligible patients had ≥1 claim (excluding claims for diagnostic tests) with a diagnosis code for ≥1 of seven comorbidities (atopic disease, nasal polyps, chronic sinusitis, obesity, respiratory infections, chronic obstructive pulmonary disease, and depression/anxiety) during the 12-month pre-index baseline period; these were used to stratify patients into seven nonmutually exclusive subgroups. Outcomes included asthma exacerbations and exacerbation-related healthcare resource utilization (HCRU) during the 12-month baseline and follow-up periods. Each patient acted as their own control. RESULTS: Of the 639 patients included, the most common comorbidities were atopic diseases (73.2%), respiratory infections (55.6%), and chronic sinusitis (45.1%). Across all seven comorbidity subgroups, there were significant (P <0.05) reductions of 38-55% and 57-83% in exacerbations and exacerbations requiring hospitalization, respectively, during the follow-up versus baseline period, except for exacerbations requiring hospitalization in the nasal polyps subgroup, due to the small subgroup sample size. During the follow-up versus baseline periods, mean number of OCS claims was significantly (P <0.001) reduced by 29-38%; 39-47% of patients achieved ≥50% OCS dose reduction. Significant reductions in exacerbation-related HCRU were also observed. CONCLUSION: Mepolizumab treatment provided real-world clinical benefits in patients.
BACKGROUND:Patients with severe asthma frequently have associated comorbidities, which can compound existing symptoms, complicating asthma management. OBJECTIVE: To describe mepolizumab's real-world effectiveness in patients with severe asthma stratified by common overlapping comorbidities. METHODS: This was a retrospective analysis of patients with asthma from the MarketScan Commercial and Medicare Supplemental Database initiating mepolizumab treatment (index date). Eligible patients had ≥1 claim (excluding claims for diagnostic tests) with a diagnosis code for ≥1 of seven comorbidities (atopic disease, nasal polyps, chronic sinusitis, obesity, respiratory infections, chronic obstructive pulmonary disease, and depression/anxiety) during the 12-month pre-index baseline period; these were used to stratify patients into seven nonmutually exclusive subgroups. Outcomes included asthma exacerbations and exacerbation-related healthcare resource utilization (HCRU) during the 12-month baseline and follow-up periods. Each patient acted as their own control. RESULTS: Of the 639 patients included, the most common comorbidities were atopic diseases (73.2%), respiratory infections (55.6%), and chronic sinusitis (45.1%). Across all seven comorbidity subgroups, there were significant (P <0.05) reductions of 38-55% and 57-83% in exacerbations and exacerbations requiring hospitalization, respectively, during the follow-up versus baseline period, except for exacerbations requiring hospitalization in the nasal polyps subgroup, due to the small subgroup sample size. During the follow-up versus baseline periods, mean number of OCS claims was significantly (P <0.001) reduced by 29-38%; 39-47% of patients achieved ≥50% OCS dose reduction. Significant reductions in exacerbation-related HCRU were also observed. CONCLUSION:Mepolizumab treatment provided real-world clinical benefits in patients.